Among the companies whose shares are expected to actively trade
in Monday's session are Regeneron Pharmaceuticals Inc. (REGN),
General Electric Co. (GE) and Complete Genomics Inc. (GNOM).
Regeneron's fourth-quarter loss wasn't quite as bad as analysts
had expected, and the company raised its current-year sales outlook
for its Eylea eye-disease drug. Shares climbed 8.9% to $111.20
premarket.
General Electric plans to expand its aviation business in the
U.S. by adding more than 400 new manufacturing jobs and will open
three new plants next year that are currently under construction in
Ellisville, Miss., Auburn, Ala., and Dayton, Ohio. Shares gained
0.8% to $19.02 in recent premarket trading.
Complete Genomics said it has been selected by Mayo Clinic's
Center for Individualized Medicine to provide outsourced whole
human genome sequencing. Shares jumped 9.4% to $3.60 premarket.
Standard & Poor's Ratings Services raised its credit rating
on Cheniere Energy Inc. (LNG) a notch, pointing to the
liquefied-natural-gas company's recent deleveraging measures.
Shares climbed 2.4% to $14.26 premarket.
AmerisourceBergen Corp. (ABC) said Chief Financial Officer
Michael D. DiCandilo has left the drug wholesaler to pursue other
interests. Shares slipped 0.4% to $38.45 premarket.
Diebold Inc. (DBD) saw a 17% jump in fourth-quarter orders for
the so-called financial self-service space, another welcome sign
for ATM demand as banks may be ready to boost spending for new
technology. That as the company reported stronger-than-expected
fourth-quarter results and gave above-consensus 2012 targets for
revenue and earnings. Shares rose 11% to $38.68 premarket.
Nordic American Tankers Ltd.'s (NAT) fourth-quarter loss
widened, and lower average daily rates hurt the tanker company's
revenue more than expected. Shares slid 1.6% to $13.50
premarket.
Watch List:
Apple Inc. (AAPL) sued Motorola Mobility Inc. (MMI), saying
Apple's iPhone 4S is protected under a license agreement from
Qualcomm Inc. (QCOM). The lawsuit, which was filed Friday, is part
of an effort by the Cupertino, Calif., consumer-electronics giant
to ward off any injunctions from Motorola, according to the court
documents.
CVR Energy Inc. (CVI) plans to sell a portion of its stake in
its limited partnership to fund a special dividend, while also
revealing it will initiate regular quarterly payouts for
shareholders.
EQT Corp.'s (EQT) EQT Midstream Partners LP unit filed plans for
an estimated initial public offering of up to $250 million in
units.
Genesee & Wyoming Inc.'s (GWR) January traffic declined 12%
from a year earlier as the railroad operator again reported
sluggish coal demand.
ITT Corp. (ITT) pushed back the date it plans to report
quarterly earnings by two weeks, citing the complexity of reviewing
financial data following the industrial conglomerate's recent
spinoffs. Thought the company still said its 2011 revenue grew, the
results fall slightly short of analysts' expectations.
Macy's Inc. (M) has no exclusive right to sell Martha Stewart
Living Omnimedia Inc. (MSO) merchandise, the domestic doyenne's
company said in a legal filing Friday. The filing is Martha Stewart
Living's response to Macy's seeking to prevent Martha Stewart
products from being sold at J.C. Penney Co. (JCP) starting next
year.
SeraCare Life Sciences Inc. (SRLS) agreed to be taken private by
the Chicago private-equity firm Linden Capital Partners in a nearly
$81 million cash deal. The company said shareholders will receive
$4 a share, a 12% premium to Friday's close, in the transaction,
which is expected to close in the second quarter.
TranSwitch Corp. (TXCC) filed plans to sell up to $10 million in
common stock through an at-the-market offering to help develop new
products.
W.W. Grainger Inc.'s (GWW) sales jumped 17% in January from a
year earlier with help from acquisitions and stronger volume.
Watson Pharmaceuticals Inc. (WPI) has filed an abbreviated
new-drug application with the U.S. Food and Drug Administration for
its generic version of Bayer Pharma AG's (BAYRY, BAYN.XE) Beyaz
oral contraceptive. Bayer and Merck KGaA (MKGAY, MRK.XE) filed a
lawsuit against Watson in a Delaware district court Friday to
prevent Watson from launching a generic version of Beyaz prior to
the expiration of its patent.
-Edited by Ian Thomson and Corrie Driebusch; write to
ian.thomson@dowjones.com and corrie.driebusch@dowjones.com